Stocks Health care ZVRA
NASDAQ · Health careZevra Therapeutics, Inc. (ZVRA)
Zevra Therapeutics, Inc. brought in $147.8M of revenue over the twelve months to September 30, 2026, up 75.1% from a year earlier. Net income was $78M, a net margin of 52.8%. In fiscal 2025 capital spending exceeded operating cash flow by $2.4M. At September 30, 2026 it held $122.1M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on November 3, 2026.
Key facts about Zevra Therapeutics, Inc.
- Net worth
- Zevra Therapeutics, Inc. has a market value (market cap) of $720.9M at the latest share price, and shareholders' equity of $238.9M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $106.5M (+350.9% year on year), with net income of $83.2M. Over the 12 months to September 30, 2026: revenue $147.8M, net income $78M.
- Cash flow
- In fiscal 2025 operations used $1.6M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on November 3, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- Zevra Therapeutics, Inc.'s next report is expected around March 8, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What Zevra Therapeutics, Inc. does
Zevra Therapeutics, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker ZVRA.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $106.5M | $83.2M | $1.35 | -$2.4M |
| 2024 | $23.6M | -$105.5M | -$2.28 | -$69.7M |
| 2023 | $27.5M | -$46M | -$1.30 | -$33.8M |
| 2022 | $10.2M | -$26.8M | -$0.78 | -$18.8M |
| 2021 | $28.7M | -$8.6M | -$2.11 | $10.3M |
| 2020 | $13.3M | -$12.8M | -$3.21 | -$2M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where ZVRA ranks in Health care
Latest SEC filings
What Zevra Therapeutics, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 5, 2026Passive stake changed SCHEDULE 13G/A
- November 3, 2026Quarterly report 10-Q · period to September 30, 2026Revenue rose 45% to $37.8M versus the same quarter last year; diluted EPS $0.26 versus -$0.01.
- November 3, 2026
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 6, 2026Passive stake changed SCHEDULE 13G/A
- August 5, 2026Quarterly report 10-Q · period to June 30, 2026Revenue rose 53% to $39.7M versus the same quarter last year; diluted EPS $0.14 versus $1.21.
- August 5, 2026
- July 31, 2026Passive stake (5% or more) SCHEDULE 13G
- June 5, 2026
- May 6, 2026Quarterly report 10-Q · period to March 31, 2026Revenue rose 78% to $36.2M versus the same quarter last year; diluted EPS $0.60 versus -$0.06.
Insider trades
What the people running Zevra Therapeutics, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders sold $699.7K worth of shares in the last 90 days and bought none on the open market. All of the selling was pre-planned under Rule 10b5-1 trading plans.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| October 12, 2026 | McFarlane Neil F.President and CEO, Director | Soldpre-planned (10b5-1) | 20,000 | $224.9K |
| October 10, 2026 | McFarlane Neil F.President and CEO, Director | Exercised options | 50,000 | - |
| August 14, 2026 | Thompson RahsaanChief Legal & Compliance | Soldpre-planned (10b5-1) | 42,666 | $474.8K |
| August 10, 2026 | Watton Corey MichaelDirector | Exercised options | 12,300 | $61.1K |
| August 10, 2026 | Watton Corey MichaelDirector | Sold | 12,300 | $138.4K |
| June 22, 2026 | Thompson RahsaanChief Legal & Compliance | Soldpre-planned (10b5-1) | 34,557 | $438.3K |
| June 21, 2026 | Thompson RahsaanChief Legal & Compliance | Exercised options | 66,667 | - |
| May 11, 2026 | Thompson RahsaanChief Legal & Compliance | Soldpre-planned (10b5-1) | 1,794 | $20.3K |
Who owns ZVRA
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Fmr LLC13G, passive with 1 related filers | 8.3% | August 6, 2026 |
| Woodline Partners LP13G, passive | 8.1% | August 14, 2026 |
| Vanguard Capital Management13G, passive | 5.11% | July 31, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 157 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| BlackRock, Inc. | 5,108,871 | +652,395 |
| Fmr LLC | 4,915,717 | +1,703,840 |
| Woodline Partners LP | 4,785,771 | +1,334,828 |
| Nantahala Capital Management, LLC | 3,594,952 | +1,073,016 |
| Vanguard Capital Management LLC | 2,638,910 | +169,582 |
| State Street Corp | 1,681,999 | +120,430 |
| Geode Capital Management, LLC | 1,540,936 | +169,079 |
| D. E. Shaw & Co., Inc. | 1,306,949 | +460,492 |
| Qube Research & Technologies Ltd | 1,241,343 | +399,024 |
| Morgan Stanley | 1,203,875 | +11,613 |
| Legal & General Group Plc | 1,201,668 | +38,578 |
| Dimensional Fund Advisors LP | 958,836 | +404,034 |
| Royce & Associates LP | 882,658 | -106,016 |
| 683 Capital Management, LLC | 855,000 | -120,000 |
| Kingdon Capital Management, L.L.C. | 775,000 | 0 |
| Retirement Planning Co of New England, Inc. | 634,410 | -16,738 |
| Jupiter Topco LLC | 613,403 | new |
| Arrowstreet Capital, Limited Partnership | 597,162 | new |
| Goldman Sachs Group Inc | 545,551 | -197,573 |
| Vanguard Portfolio Management LLC | 541,109 | +74,806 |
Insiders
8 insiders reported holding 825,100 shares in total, about $10M at the last price.
| Holder | Shares |
|---|---|
| McFarlane Neil F.President and CEO, Director | 417,225 |
| Clifton R. LaDuaneFormer CFO & Treasurer | 143,515 |
| Bode John BDirector | 123,400 |
| Schafer JoshuaCCO | 62,278 |
| Thompson RahsaanChief Legal & Compliance | 37,569 |
| Sangiovanni Timothy J.SVP, Finance & Corp Controller | 29,590 |
| Quartel Adrian WChief Medical Officer | 9,723 |
| Watton Corey MichaelDirector | 1,800 |
Questions about ZVRA
What does Zevra Therapeutics, Inc. do?
Zevra Therapeutics, Inc. is a company in the Health care sector, listed on NASDAQ as ZVRA. Its shares trade on NASDAQ under the ticker ZVRA.
What is Zevra Therapeutics, Inc.'s net worth?
Zevra Therapeutics, Inc. has a market value (market cap) of $720.9M at the latest share price, and shareholders' equity of $238.9M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Zevra Therapeutics, Inc. profitable?
Yes. Over the twelve months to September 30, 2026 it reported net income of $78M on revenue of $147.8M, a net margin of 52.8%.
How much revenue does Zevra Therapeutics, Inc. make?
Over the twelve months to September 30, 2026 Zevra Therapeutics, Inc. reported revenue of $147.8M. That is 75.1% more than a year earlier.
When did Zevra Therapeutics, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on November 3, 2026. It covers the period to September 30, 2026. Its newest filing of any kind is the passive stake changed from November 5, 2026.
When is Zevra Therapeutics, Inc.'s next earnings report?
Zevra Therapeutics, Inc.'s next report is expected around March 8, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare ZVRA with
Follow ZVRA
Get an email when Zevra Therapeutics, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Zevra Therapeutics, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.